Study of IMC-002 in advanced cancer
Part of Cancer clinical trials.
This study tests a new drug called IMC-002 in people with advanced cancer that has not responded to standard treatment. It aims to see if the drug is safe and effective, and may be given alone or with other treatments depending on the cancer type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have advanced cancer that has spread or is locally advanced and has failed standard therapy.
- You have a specific type of cancer: solid tumors (any type), liver cancer, triple-negative breast cancer, bile duct cancer, pancreatic cancer, or certain B-cell lymphomas.
- You have at least one measurable tumor that can be evaluated by scans.
- You are willing to provide a tumor sample (archived or fresh biopsy).
- You have a good performance status (able to carry out daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
This study tests an experimental drug called IMC-R117C for people with certain advanced cancers. It aims to see if the drug can shrink tumors or slow cancer growth.
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug called MC002 for advanced solid tumors that have not responded to standard treatments. The purpose is to find a safe dose and see if it can help shrink or control the cancer.
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.